RxDoctor Payments Data

Elizabeth Raper

Family · Florence, ALNPI 1164521787

Payments from drug & device makers

$1,843in general payments, 2019–2025

Across 145 payments — averaging $12.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$660
  • GSK$235
  • AbbVie$213
  • Novartis$116
  • Lilly USA, LLC$107
  • AstraZeneca$83
  • plus $430 from 12 others

What the payments were for

  • Food & beverage$1,843100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,843 in reported general payments places this provider in the 75th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$73,688
Medicare patients
367
Services billed
4,961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,255
Cefdinir229$3,829
Albuterol Sulfate HfaAlbuterol Sulfate67$1,868
Omega-3 Acid Ethyl Esters11$1,122
Atorvastatin Calcium82$1,022
Metoprolol Succinate43$812
Omeprazole52$675
Potassium Chloride25$619
Methylprednisolone88$617
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst36$542
Azithromycin120$487
Levothyroxine Sodium38$458
Meloxicam80$434
Fluticasone Propionate19$433
Fenofibrate14$429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$235$12,25520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,415 family providers in Alabama.

Other family in Florence

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →